Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: Is adding drugs always beneficial?

Yuqing Zhang, Xuezhong Zhang, Lisheng Liu, Yang Wang, Xinran Tang, Alberto Zanchetti

Research output: Contribution to journalArticle

Abstract

BACKGROUND: In antihypertensive treatment trials, when randomized therapies do not reach target, additional drugs are administered. However, patients requiring (add-on) or not requiring add-on therapy (no-add-on) may be at different cardiovascular risk and differently susceptible to benefits of antihypertensive treatment. METHODS AND RESULTS: The Felodipine Event Reduction study included 9711 Chinese hypertensive patients receiving 12.5 mg/day hydrochlorothiazide and randomized to associating either felodipine (5 mg/day) or placebo. Within 6 months, add-on therapy (further diuretic and other drugs) was required by 2185 patients, whereas 7243 did not require it. Despite significant SBP/DBP reductions by add-on therapy, outcome incidence remained much lower in no-add-on than in add-on patients: hazard ratios for various outcomes, after adjusting for baseline variables and blood pressure (BP) at time of add-on decision, were 0.22-0.368 (P always

Original languageEnglish
Pages (from-to)2202-2212
Number of pages11
JournalJournal of Hypertension
Volume30
Issue number11
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Antihypertensive Agents
Pharmaceutical Preparations
Felodipine
Therapeutics
Hydrochlorothiazide
Diuretics
Placebos
Blood Pressure
Incidence

Keywords

  • antihypertensive therapy
  • cardiovascular disease
  • resistant hypertension
  • therapeutic strategies
  • trials

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy : Is adding drugs always beneficial? / Zhang, Yuqing; Zhang, Xuezhong; Liu, Lisheng; Wang, Yang; Tang, Xinran; Zanchetti, Alberto.

In: Journal of Hypertension, Vol. 30, No. 11, 11.2012, p. 2202-2212.

Research output: Contribution to journalArticle

@article{001efcf438c94b8ea9be30ee1e2f92b8,
title = "Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: Is adding drugs always beneficial?",
abstract = "BACKGROUND: In antihypertensive treatment trials, when randomized therapies do not reach target, additional drugs are administered. However, patients requiring (add-on) or not requiring add-on therapy (no-add-on) may be at different cardiovascular risk and differently susceptible to benefits of antihypertensive treatment. METHODS AND RESULTS: The Felodipine Event Reduction study included 9711 Chinese hypertensive patients receiving 12.5 mg/day hydrochlorothiazide and randomized to associating either felodipine (5 mg/day) or placebo. Within 6 months, add-on therapy (further diuretic and other drugs) was required by 2185 patients, whereas 7243 did not require it. Despite significant SBP/DBP reductions by add-on therapy, outcome incidence remained much lower in no-add-on than in add-on patients: hazard ratios for various outcomes, after adjusting for baseline variables and blood pressure (BP) at time of add-on decision, were 0.22-0.368 (P always",
keywords = "antihypertensive therapy, cardiovascular disease, resistant hypertension, therapeutic strategies, trials",
author = "Yuqing Zhang and Xuezhong Zhang and Lisheng Liu and Yang Wang and Xinran Tang and Alberto Zanchetti",
year = "2012",
month = "11",
doi = "10.1097/HJH.0b013e3283582eec",
language = "English",
volume = "30",
pages = "2202--2212",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy

T2 - Is adding drugs always beneficial?

AU - Zhang, Yuqing

AU - Zhang, Xuezhong

AU - Liu, Lisheng

AU - Wang, Yang

AU - Tang, Xinran

AU - Zanchetti, Alberto

PY - 2012/11

Y1 - 2012/11

N2 - BACKGROUND: In antihypertensive treatment trials, when randomized therapies do not reach target, additional drugs are administered. However, patients requiring (add-on) or not requiring add-on therapy (no-add-on) may be at different cardiovascular risk and differently susceptible to benefits of antihypertensive treatment. METHODS AND RESULTS: The Felodipine Event Reduction study included 9711 Chinese hypertensive patients receiving 12.5 mg/day hydrochlorothiazide and randomized to associating either felodipine (5 mg/day) or placebo. Within 6 months, add-on therapy (further diuretic and other drugs) was required by 2185 patients, whereas 7243 did not require it. Despite significant SBP/DBP reductions by add-on therapy, outcome incidence remained much lower in no-add-on than in add-on patients: hazard ratios for various outcomes, after adjusting for baseline variables and blood pressure (BP) at time of add-on decision, were 0.22-0.368 (P always

AB - BACKGROUND: In antihypertensive treatment trials, when randomized therapies do not reach target, additional drugs are administered. However, patients requiring (add-on) or not requiring add-on therapy (no-add-on) may be at different cardiovascular risk and differently susceptible to benefits of antihypertensive treatment. METHODS AND RESULTS: The Felodipine Event Reduction study included 9711 Chinese hypertensive patients receiving 12.5 mg/day hydrochlorothiazide and randomized to associating either felodipine (5 mg/day) or placebo. Within 6 months, add-on therapy (further diuretic and other drugs) was required by 2185 patients, whereas 7243 did not require it. Despite significant SBP/DBP reductions by add-on therapy, outcome incidence remained much lower in no-add-on than in add-on patients: hazard ratios for various outcomes, after adjusting for baseline variables and blood pressure (BP) at time of add-on decision, were 0.22-0.368 (P always

KW - antihypertensive therapy

KW - cardiovascular disease

KW - resistant hypertension

KW - therapeutic strategies

KW - trials

UR - http://www.scopus.com/inward/record.url?scp=84867748328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867748328&partnerID=8YFLogxK

U2 - 10.1097/HJH.0b013e3283582eec

DO - 10.1097/HJH.0b013e3283582eec

M3 - Article

C2 - 22990352

AN - SCOPUS:84867748328

VL - 30

SP - 2202

EP - 2212

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 11

ER -